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Fluvastatin suppresses oxidative stress and fibrosis in the inter- renal injury leading to tubulointerstitial fibrosis that was
stitium of mouse kidneys with unilateral ureteral obstruction. pioneered by Klahr and Purkerson [1, 2]. The UUO is an
Background. Recently, we demonstrated increased oxida- excellent model of interstitial fibrosis because it is normo-tive stress in the interstitium of ureteral obstructed kidneys
tensive, nonproteinuric, and nonhyperlipidemic withoutbased on the increased expression of heme oxygenase-1 and
any apparent immune or toxic renal insult. The molecu-immunohistochemical detection of advanced glycation end prod-
ucts (AGE) in the interstitium. Antioxidant therapy may have lar and cellular mechanism(s) of interstitial fibrosis in
a therapeutic potential toward interstitial fibrosis of unilateral UUO kidney is beginning to be elucidated. The mechani-
ureteral obstruction (UUO) kidneys. Fluvastatin is an HMG- cal disturbances resulting from ureteral ligation (tensionCoA reductase inhibitor and has been demonstrated to have
stress) [3], hypoxia induced by a marked decline in renalan antioxidant activity in vitro.
plasma flow [2], up-regulation of monocyte chemoattrac-Methods. The effects of fluvastatin on UUO kidneys from
the viewpoints of antioxidant action in vivo and antifibrosis tant peptide [4], osteopontin [5], heat shock protein 47
action were studied. To investigate the antioxidant action and (HSP47) [6, 7], intercellular adhesion molecule 1 [8],
its therapeutic efficacy of fluvastatin in UUO kidneys, AGE
macrophage influx into the interstitium [4, 9], and pro-accumulation and fibrosis in the obstructed kidneys was com-
duction of macrophage-derived cytokines, especiallypared among vehicle-, pravastatin-, or fluvastatin-treated (10
or 40 mg/kg/day) groups. transforming growth factor-b (TGF-b) [10, 11], have
Results. Tubulointerstitial fibrosis was significantly attenu- been shown to play important roles in the tubulointersti-
ated in fluvastatin-treated animals. Fluvastatin significantly sup- tial damage in UUO kidney. We have been investigating
pressed the degree of immunostaining of AGE in UUO kidneys.
the molecular mechanisms of interstitial cell activationConclusions. These results provide evidence for the antioxi-
in UUO from the viewpoint of stress responses [6, 7].dant action of fluvastatin in vivo. The decreased interstitial
fibrosis along with a decreased oxidative stress marker in the While oxidative stress has been implicated in the
interstitial lesion strongly suggests the existence of a causal pathogenesis of various forms of renal injury, little is
relationship between them. Fluvastatin may have therapeutic known about its involvement in the setting of ureteralvalue in slowing or preventing interstitial fibrosis in progressive
obstruction. We have recently found that the tubulointer-renal disease.
stitium of obstructed kidneys is under increased oxidative
stress [12]. Detection of oxidative stress in vivo is not easy
because of the unstable and reactive nature of reactiveRenal interstitial fibrosis is one of the common histo-
oxygen species (ROS). We used heme oxygenase-1 (HO-1)pathological features of progressive renal disease of di-
expression and tissue accumulation of Ne-(carboxymethyl)verse etiology. Chronic unilateral ureteral obstruction
lysine (CML) as indicators of oxidative stress in vivo.(UUO) is a well-characterized experimental model of
CML is an integrative biomarker of the cumulative pro-
tein damage induced by glycoxidation [13]. HO-1 mRNA
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and protein expression, which is a sensitive and reliabletherapy, tubulointerstitial fibrosis, advanced glycation end products,
heme oxygenase-1. indicator of oxidative stress [14], were also examined.
This observation led us to investigate the therapeuticReceived for publication August 17, 2000
efficacy of a compound having antioxidant activity to-and in revised form December 6, 2000
Accepted for publication January 8, 2001 ward increased oxidative stress and, if possible, against
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inhibitor, as a test compound since fluvastatin is known Tissue preparation
to have antioxidant activity in vitro [15–17]. Pravastatin, For morphological examination, the mice were anes-
another HMG-CoA reductase inhibitor that lacks anti- thetized with pentobarbital, and the kidneys were per-
oxidant activity, was used as a control compound. fused in situ with cold phosphate-buffered saline (PBS)
In the present study, we studied the effect of fluvastatin to remove circulating blood cells. The kidneys were re-
on the tubulointerstitial lesion of obstructed kidneys moved, sliced transversely in 2 to 3 mm thick sections,
from the viewpoint of oxidative stress. Immunohistologi-
immersed in a cold 4% paraformaldehyde (PFA) or 70%cal detection of advanced glycation end product (AGE)
ethanol solution for 16 to 24 hours, and embedded inwas performed using anti-AGE monoclonal antibody,
paraffin. Four micrometer thick paraffin sections werewhich recognizes mainly CML, and the effects of fluvas-
subjected to Masson’s trichrome staining.tatin and pravastatin on the accumulation of AGE were
compared. HO-1 mRNA expression was also studied one Immunohistochemical studyday after ureteral ligation. We found significant amelio-
Antibodies. a-Smooth muscle actin (a-SMA) was iden-ration of interstitial fibrosis along with decreased accumu-
tified with mouse anti–a-SMA monoclonal antibody (1A4;lation of AGE in the interstitium of the obstructed kid-
EPOS, peroxidase-conjugated; Dako, Glostrup, Den-neys. HO-1 mRNA induction was blunted by fluvastatin
mark). Mouse anti-AGE monoclonal antibody (4D12;treatment. These findings demonstrate the antioxidant
peroxidase-conjugated) was purchased from Wako Chem-activity of fluvastatin in vivo and suggest the therapeutic
value of fluvastatin in the treatment of interstitial fibrosis. ical Company (Osaka, Japan).
Paraffin sections obtained from obstructed kidneys
and contralateral control kidneys were deparaffinized byMETHODS
xylene. All sections were incubated in a 99:1 methanol/Experimental protocol and disease model
H2O2 solution for 30 minutes at room temperature to in-
This study was designed to determine whether fluvas- activate the endogenous peroxidase activity, then washed
tatin reduces oxidative stress in the interstitium of ob- in PBS for 10 minutes three times, and preincubated at
structed kidneys and improves the tubulointerstitial fi- room temperature in blocking solution (10% goat serum
brosis of the affected kidneys. Pravastatin was used as a and 1% bovine serum albumin (BSA), 0.01% Triton
control compound because it is an HMG-CoA reductase
x-100) for 30 minutes. The blocking solution was theninhibitor without antioxidant activity. Two experimental
blotted onto a paper, and the first antibody was appliedprotocols were performed. The first experiment was un-
to the sections. Incubation with the first antibody wasdertaken as a pilot study to determine the effective dos-
performed for 16 hours at 48C. After removal of the firstage and actual consumption of the fluvastatin. The sum-
antibody and three serial washes in ice-cold PBS (10 minmary of the first experiment is described in the Results
each), the sections for a-SMA and AGE were incubatedsection. Based on the first experiment, the following
with solution containing 0.35 mg/mL p-dimethyl amino-doses of the fluvastatin were chosen for the second exper-
benzaldehyde and in 50 mmol/L Tris-HCl (pH 7.6) to vis-iment. Mice were given a standard diet (CRF-1; Oriental
ualize the peroxidase activity on the section. After coun-Yeast Co., Ltd., Tokyo, Japan) containing 0.004% (10
terstaining in methyl green, the sections were mounted.mg/kg body weight) or 0.016% (40 mg/kg body weight)
test compounds from three days before (23) the UUO As a negative control for AGE or a-SMA staining, nor-
operation to the day of sacrifice. Male B6C3 F1 mice, mal mouse serum was used instead of the anti-AGE or
weighing 20 to 22 g, were used in these experiments. a-SMA antibody. No significant staining was observed
The general procedure of the mouse UUO operation is in the sections incubated with normal mouse serum in-
the same as described previously [7]. After induction of stead of the first antibody.
general anesthesia by the intraperitoneal injection of
pentobarbital (50 mg/kg body weight), all mice under- RNA isolation and Northern blotting
went left proximal ureteral ligation. The left ureter was For RNA extraction, the kidneys were perfused in situ
identified through a small suprapubic incision and was with cold PBS, were removed and snap frozen in liquid
ligated with 4-0 silk at two points. Both the obstructed
nitrogen, and were kept at 2808C until use. A whole kid-and contralateral kidneys were harvested from UUO ani-
ney was homogenized with a Polytron homogenizer (Ki-mals at 1 (vehicle, N 5 7; fluvastatin 10 mg/kg, N 5 8;
nematica, Lucerne, Switzerland) in TRIzol reagent (3 mLfluvastatin 40 mg/kg, N 5 8; pravastatin, N 5 7), 4 (vehicle,
for a whole kidney; GIBCO BRL, Gaithersburg, MD,N 5 7; fluvastatin 10 mg/kg, N 5 8; fluvastatin 40 mg/kg,
USA), and the total cellular RNA was prepared by acidN 5 6; pravastatin, N 5 7), and 10 days (vehicle, N 5
guanidinium thiocyanate-phenol-chloroform extraction6; fluvastatin 10 mg/kg, N 5 8; fluvastatin 40 mg/kg,
procedure according to the manufacturer’s instructionsN 5 8; pravastatin, N 5 7) after ureteral obstruction.
[18]. Twenty micrograms of RNA were size fractionatedMidcoronal sections of the kidneys were also taken for
immunohistochemical labeling. on 1% agarose-formaldehyde gel and transferred to a
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nylon membrane filter (Hybond N1; Amersham, Bos- scopet; Mitani Corporation, Fukui, Japan), and the per-
centage of the fibrotic area or immunostaining positiveton, MA, USA) and cross-linked by ultraviolet wave
irradiation. Prehybridization of the membranes was done area relative to the whole area of the field was calculated
(percentage area). Glomeruli and large vessels were notfor two hours at 428C in a buffer containing 5 3 SSPE
[1 3 SSPE 5 150 mmol/L NaCl, 11 mmol/L NaH2PO4, 2 included in the microscopic fields for image analysis. The
scores of the five fields of each kidney were averaged.mmol/L ethylenediaminetetraacetic acid (EDTA)], 10 3
Denhardt’s (100 3 Denhardt’s 5 2% Ficoll, 2% polyvi- The scores of six separate animals were then averaged.
nylpyrroridone, 2% BSA), 0.5% sodium dodecyl sulfate
Analytical procedure(SDS), 100 mg/mL denatured salmon sperm DNA, and
50% (vol/vol) formamide. The membranes were hybrid- All values were expressed as mean 6 SD. The data
were analyzed for homogeneity using Bartlett’s test. Theized with 106 cpm/mL cDNA probes (described later in
this article) in hybridization buffer (same as the prehy- statistical significance of any intergroup differences was
determined using Dunnett’s test for homogeneous databridization buffer) for 24 hours at 428C. After hybridiza-
tion, the filters were washed three times for 15 minutes or Kruskal-Wallis test followed by Dunnett’s type test
for heterogenous data. Statistically significant differencesin 1 3 standard sodium citrate (SSC; 20 3 SSC 5 3
mol/L NaCl, 0.3 mol/L sodium citrate, pH 7.0) with 0.1% between groups were defined as P values of less than 0.05.
SDS at 608C. The membranes were then autoradio-
graphed with the intensifying screens (Du Pont, Wil-
RESULTS
mington, DE, USA) at 2708C for one to three days. The
Summary of the pilot studydensity of the bands was quantitated with the computing
densitometer Image Quant (Molecular Dynamics, Sun- Standard mouse chow containing different amounts
of fluvastain (0.002% and 0.02%) was given to mice, andnyvale, CA, USA).
The following 32P multiprime-labeled DNA probes were daily food consumption was measured for one cage (6
mice). The body weight of each mouse was measuredprepared by a rediprime DNA labeling system (Amersham,
Buckinghamshire, UK). Rat HO-1 cDNA (pRHO-1) was every day. The average daily food consumption was 5.5 6
0.8 g for vehicle-treated UUO mice, 5.4 6 0.7 g for low-kindly provided by Dr. Shibahara (Tohoku University
School of Medicine, Sendai, Japan) [19]. ApaI/EcoRI dose fluvastatin-treated UUO mice, and 5.0 6 0.7 g for
high-dose fluvastatin-treated UUO mice. The averagefragment of pRHO-1 (649 bp) was used as a probe for
Northern blotting. Rat glyceraldehyde-3-phosphate-dehy- body weight for each group was approximately 22 g for
vehicle and low-dose fluvastatin-treated mice and ap-drogenase (GAPDH) cDNA [20] was used to monitor
the variation of sample loading. proximately 20 g for high-dose fluvastatin-treated mice
10 days after commencing drug administration. The cal-
Measurement of serum lipids culated dose was approximately 5 mg/kg/day for the low-
dose fluvastatin-treated group and approximately 50 mg/Fasting vein blood sample was collected from each
mouse just before nephrectomy. Serum levels of total kg/day for high-dose treated mice. Based on these mea-
surements, we defined the fluvastatin doses of the firstcholesterol, triglyceride, were determined by using com-
mercially available enzymatic methods (EIKEN Chemi- experiment as 5 and 50 mg/kg/day. Fluvastatin adminis-
tration was started three days before the UUO operationcal Co., Tokyo, Japan).
and was continued to the day of sacrifice at 10 postopera-
Morphometric analysis of the interstitial fibrosis in tive days (N 5 6 for each group, each time point). The
Masson’s trichrome or immunohistochemically stained a-SMA-positive area was quantitatively analyzed to ex-
sections by a computer-aided manipulator plore possible effects of fluvastatin on the interstitial
myofibroblast expansion. We found a dose-dependentThe area of the fibrotic lesion in the cortical intersti-
tium was determined on sections stained by Masson’s decrease in a-SMA-positive area in fluvastatin-treated
animals (vehicle 25.5 6 3.7, fluvastatin 5 mg/kg 19.5 6trichrome method to stain the collagen fibers (stained
in light blue) as already described [7]. The interstitial area 5.0, P 5 NS vs. vehicle; fluvastatin 50 mg/kg 15.7 6 1.9,
P , 0.01 vs. vehicle).positive for immunohistochemical detection was analyzed
and quantitated as described [21]. Under high-power Based on the results of the preliminary experiment,
we chose two doses of fluvastatin, 10 and 40 mg/kg/day,magnification (3400), five randomly selected nonover-
lapping fields from the cortical region were analyzed. for the treatment of interstitial fibrosis in UUO. In addi-
tion, we decided to test the effect of pravastatin, anThe fibrotic areas stained in light blue in the interstitium
and tubular basement membrane or immunostaining HMG-CoA reductase inhibitor lacking in vitro antioxi-
dant activity.positive area in the interstitium stained in brown were
picked up on the digital images using a computer-aided The second experiment used the body weight of indi-
vidual mice just before sacrifice to monitor the differ-manipulator (image-operating computer program, Mac-
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Fig. 1. Masson’s trichrome staining of kid-
neys from four experimental groups at 10 days
after ureteral obstruction. Light field photomi-
crographs of Masson’s trichrome-stained sec-
tions from (A) vehicle-treated, (B) pravastatin-
treated (10 mg/kg/day), (C) fluvastatin-treated
(10 mg/kg/day), and (D) fluvastatin-treated (40
mg/kg/day) mouse obstructed kidneys 10 days
after ureteral obstruction (3400).
Effects of fluvastatin on interstitial expansion of
UUO kidneys
The representative appearance of Masson’s trichrome-
stained sections of obstructed kidneys from four experi-
mental groups 10 days after ureteral obstruction is shown
in Figure 1. Interstitial expansion of obstructed kidneys
was prominent in vehicle-treated animals and was also
observed to a similar extent in pravastatin-treated ani-
mals. In fluvastatin-treated animals, interstitial expan-
sion was less compared with vehicle-treated animals.
Quantitative analysis of interstitial fibrosis area in four
Fig. 2. Quantitative analysis of interstitial fibrosis in kidneys with ure- groups is shown in Figure 2. Fluvastatin treatment at
teral obstruction treated with fluvastatin or pravastatin. Interstitial fi-
both high (40 mg/kg/day) and low (10 mg/kg/day) dosesbrosis was quantitated with a computer-aided image manipulator. Eight
animals were analyzed for each point, and five randomly selected high- significantly ameliorated the interstitial expansion in
power fields were quantitated and were averaged for the value of each UUO kidneys at 10 days after ureteral obstruction. On
animal. Symbols are: ( ) vehicle; ( ) fluvastatin 10 mg/kg/day; ( )
the other hand, pravastatin had little effect on the inter-fluvastatin 40 mg/kg/day; ( ) pravastatin 10 mg/kg/day; *P , 0.01 vs.
vehicle. stitial expansion of UUO kidneys. There seemed to be
less tubular atrophy in the cortex in the fluvastatin-
treated mice compared with vehicle or pravastatin-treated
mice at 10 days after ureteral obstruction.ences in terms of food consumption (that is, test com-
pound consumption). The average body weight 10 days
Effects of fluvastatin on interstitial a-SMA expressionafter UUO was 22.6 6 0.9 g for vehicle, 22.0 6 0.3 g for
in UUO kidneysfluvastatin 10, 20.7 6 1.1 g for fluvastatin 40, and 22.2 6
Induction of interstitial myofibroblasts was assessed0.8 g for pravastatin 10. There was a slight decrease in
by immunohistochemical detection of a-SMA. Figure 3body weight gain in fluvastatin 40-treated mice, which
shows the representative appearance of a-SMA immuno-was already noticed in the preliminary experiment. No
reactivity in the interstitium of UUO kidneys 10 days afterdifference in body weight was observed among vehicle- or
ureteral obstruction. Intense immunostaining of a-SMAfluvastatin 10- or pravastatin 10-treated mice, suggesting
was observed in the periglomerular and peritubular inter-that a similar amount of fluvastatin and pravastatin was
stitium in addition to the vascular smooth muscle of theadministered in fluvastatin 10- and pravastatin 10-treated
mice. arterioles in vehicle-treated mouse kidneys 10 days after
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Fig. 3. Immunohistochemical detection of
a-smooth muscle actin (a-SMA) in obstructed
kidneys. Light field photomicrographs of par-
affin sections (A) reacted with mouse mono-
clonal anti–a-SMA antibody; the cortical re-
gion from a 10-day obstructed kidney from a
vehicle-treated animal, (B) from a pravastatin-
treated (10 mg/kg/day) animal, (C ) from a flu-
vastatin-treated (10 mg/kg/day) animal, (D)
and from a fluvastatin-treated (40 mg/kg/day)
animal. Sections were counterstained by methyl
green. Original magnification was 3400.
Fig. 6. Horseradish peroxidase immunostain-
ing of advanced glycation end products (AGE)
in ureteral obstructed kidneys. Light field pho-
tomicrographs of paraffin sections (A) reacted
with mouse monoclonal anti-AGE antibody;
the cortical region from a 10-day obstructed
kidney from a vehicle-treated animal, (B) from
a pravastatin-treated (10 mg/kg/day) animal,
(C) from a fluvastatin-treated (10 mg/kg/day)
animal, and (D) from a fluvastatin-treated
(40 mg/kg/day) animal. Sections were counter-
stained by methyl green. Original magnifica-
tion was 3300.
ureteral ligation (Fig. 3A). No interstitial immunostaining (10 and 40 mg/kg/day) significantly reduced the a-SMA
immunostaining at 10 days after ureteral obstruction.of a-SMA was detected in the contralateral unobstructed
or sham-operated kidneys (data not shown). Fluvastatin
Expression of heme oxygenase-1 in thebut not pravastatin treatment reduced the appearance
obstructed kidneysof a-SMA-positive myofibroblasts in the interstitium
(Fig. 3B–D). Quantitative analysis of a-SMA immuno- In our previous study, there was an induction of HO-1
mRNA expression as early as 12 hours after the onset ofstaining is shown in Figure 4. Fluvastatin at both doses
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Fig. 4. Quantitative analysis of a-SMA immunostaining in kidneys with
ureteral obstruction treated with fluvastatin or pravastatin. The immu-
nostaining positive area was quantitated with a computer-aided image
manipulator. Eight animals were analyzed for each point, and five
randomly selected high-power fields were quantitated and averaged for
the value of each animal. Symbols are: ( ) vehicle; ( ) fluvastatin 10
mg/kg/day; ( ) fluvastatin 40 mg/kg/day; ( ) pravastatin 10 mg/kg/
day; *P , 0.05 vs. vehicle-treated animals.
Fig. 5. Heme oxygenase-1 (HO-1) mRNA in mouse kidneys one day
after the onset of ureteral obstruction. The relative induction of HO-1
mRNA by densitometry of the Northern blotting autoradiograms is
ureteral obstruction. The early induction of HO-1 is likely shown. The denstimetric values of vehicle treated mice were taken as
1. Results are mean 6 SD of four independent animals. *P , 0.05indicative of early onset of oxidative stress in the inter-
vs. vehicle-treated animals. Representative samples are shown in thisstitium of obstructed kidneys. To investigate whether flu- autoradiogram. Each lane represents RNA (20 mg) from obstructed
vastatin blunts the early increase of oxidative stress in kidneys from four experimental groups. The top panel shows the HO-1
mRNA, and the bottom panel shows the GAPDH mRNA. Abbrevia-the obstructed kidneys following ureteral obstruction, the
tions are: Fluva 10, fluvastatin (10 mg/kg/day); Fluva 40, fluvastatin (40induction of HO-1 mRNA one day after ureteral obstruc- mg/kg/day); Prava 10, pravastatin (10 mg/kg/day).
tion was examined by Northern blot analysis. As shown
in Figure 5, there was a significant reduction in HO-1
mRNA levels in the high-dose fluvastatin-treated group.
Table 1. Serum lipids levels in unilateral ureteral obstructed (UUO)
mice 10 days after ureteral obstruction
Effects of fluvastatin on the immunostaining of AGE
Vehicle Fluva 10 Fluva 40 Prava 10in the interstitium of UUO kidneys
Total cholesterolFigure 6 shows the representative appearance of the im-
mg/dL 105.868.6 115.469.7 118.7611.7 120.667.9
munostaining of AGE in the UUO kidneys after 10 days Triglyceride
mg/dL 58.6610.8 61.067.8 50.862.6 56.2611.4of ureteral obstruction from four experimental groups.
At 10 days following ureteral obstruction, AGE immu- Data are mean 6 SD; N 5 5–8. Abbreviations are: Fluva 10, fluvastatin (10
mg/kg/day)-treated group; Fluva 40, fluvastatin (40 mg/kg/day)-treated group;noreactivity was observed in the periglomerular and per-
Prava 10; pravastatin (10 mg/kg/day)-treated group.
itubular interstitium of the obstructed kidneys from vehi-
cle-treated mouse (Fig. 6A). AGE immunostaining was
reduced in fluvastatin-treated animals but not in pravas-
DISCUSSIONtatin-treated animals (Fig. 6B) at both low (10 mg/kg/
day; Fig. 6C) and high (40 mg/kg/day; Fig. 6D) doses. The possible involvement of oxidative stress in the
pathogenesis of obstructive nephropathy has recently be-Quantitative analysis of AGE immunostaining in inter-
stitium is shown (Fig. 7). A significant reduction in the gun to attract attention. We have recently revealed in-
creased oxidative stress in the interstitium of obstructedAGE-positive area was observed in fluvastatin-treated
mouse kidneys. kidneys by the increased immunostaining of CML at 10
days after ureteral obstruction and an early up-regula-
Effects of fluvastatin and pravastatin on serum lipids tion of HO-1 mRNA expression [12]. The present study
levels in UUO mice tested the therapeutic value of fluvastatin, an HMG CoA
reductase inhibitor, as a potential antioxidant agent tar-Serum cholesterol or triglyceride levels were not af-
fected by fluvastatin or pravastatin treatment at 10 days geting increased oxidative stress and fibrosis in the tubu-
lointerstitium of UUO kidneys.after ureteral obstruction (Table 1). This observation is
consistent with the previous recognition that HMG-CoA The major finding in this study is the reduction of
oxidative stress in the interstitium of obstructed kidneysreductase inhibitors have little lipid-lowering effect in
mice [22]. from mice treated by fluvastatin. Of note, the effect was
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observed in the absence of the lipid-lowering effect of
the compound. This is the first demonstration of in vivo
antioxidant activity of fluvastatin toward kidney. Two
different doses were tested, and both high and low doses
were revealed to be effective in reducing the accumula-
tion of AGE in the interstitium of the obstructed kidneys.
Fluvastatin was shown to have in vitro antioxidant activ-
ity against oxidative modification of low-density lipopro-
tein [16]. Yamamoto, Hoshi, and Ichihara investigated
the effect of fluvastatin and pravastatin on the lipid per-
oxidation in vitro and found that the order of magnitude
of inhibition was butylated hydroxytoluene . probucol $
fluvastatin . pravastatin, with 0.3 mmol/L, 8.2 mmol/L, Fig. 7. Quantitative analysis of AGE immunostaining in obstructed
kidneys 10 days after ureteral obstruction. An immunostaining positive11.8 mmol/L, and 2.3 mmol/L of IC50, respectively [15].
area was quantitated with a computer-aided image manipulator. Six toThey also found that fluvastatin but not pravastatin has eight animals were analyzed for each point, and five randomly selected
high-power fields were quantitated and averaged for the value of eachscavenging activity of superoxide anion in vitro. The
animal. *P , 0.05 vs. vehicle-treated animals. **P , 0.01 vs. vehicle-glycoxidation reaction only proceeds in the presence of
treated animals. Abbreviations are: Fluva 10, fluvastatin (10 mg/kg/
oxygen mediated by a free radical mechanism involving day); Fluva 40, fluvastatin (40 mg/kg/day); Prava 10, pravastatin (10
mg/kg/day).superoxide radicals and hydrogen peroxide [23]. This
may explain the different effects between fluvastatin and
pravastatin on the accumulation of AGE in the ob-
structed kidneys.
Tubulointerstitial injury is an invariant finding in theWe found that fluvastatin but not pravastatin has a
chronically diseased kidney, irrespective of the type ofsuppressive effect on the interstitial expansion and inter-
disease or the compartment in which the disease origi-stitial expression of a-SMA in the obstructed kidneys.
nates. Recent investigations revealed a close association
The therapeutic efficacy of HMG-CoA reductase inhibi-
between the interstitial damage and the prognosis of
tors in renal diseases has been shown in experimental renal dysfunction [27, 28]. The mechanisms of the devel-
settings. Yoshimura et al found in rat anti-Thy 1.1 glo- opment of tubulointerstitial injury and interstitial fibrosis
merulonephritis that simvastatin suppressed glomerular in UUO kidney are a complex pathophysiological sequel
expression of a-SMA and glomerular hypercellularity of cellular and molecular events. The appearance of
[24]. More recently, Kim, Han, and Lee demonstrated
a-SMA-positive activated interstitial cells is one of the
that lovastatin administration in streptozotocin-induced early changes leading to a consequent fibrosis in tubu-
diabetic rats significantly suppressed the increase in urine lointerstitium. Recent findings demonstrated that the en-
albumin excretion, kidney weight, glomerular volume, hanced expression of a-SMA is a marker of interstitial
and TGF-b mRNA expression [25]. They also found in phenotypic change in various forms of renal disease, and
cultured mesangial cells that lovastatin suppressed the these activated interstitial cells are called “myofibro-
high glucose-induced up-regulation of TGF-b and fibro- blasts” [29]. The appearance of myofibroblasts has also
nectin mRNA. These studies were focused on the glo- been considered to play a key role in the progression of
merular lesion. Our study is the first demonstration, to renal fibrosis in both glomerular and interstitial lesions,
our knowledge, of the therapeutic efficacy of HMG-CoA and to predict a progressive decline in renal function in
reductase inhibitor toward tubulointerstitial lesion. In patients with several glomerulonephritis [30–33]. Myo-
contrast to earlier studies, we did not find significant fibroblasts are also described in experimental renal dam-
suppression of the tubulointerstitial lesion in pravastatin- ages [11, 34]. A better understanding of the molecular
treated animals. Pravastatin did not affect the appear- mechanism of myofibroblast formation would give a new
ance of myofibroblast assessed by a-SMA immunostain- therapeutic option targeting glomerular and tubulointer-
ing or increased oxidative stress in the interstitium re- stitial fibrosis. To date, little is known about the molecu-
vealed by HO-1 expression or AGE immunostaining. It lar mechanism of oxidative stress in the formation of
was previously reported that an in vivo inhibitory effect myofibroblasts and consequent fibrotic lesion in the kid-
of pravastatin and fluvastatin on de novo cholesterol ney. Our previous and present studies showed the possi-
synthesis is comparable in rat kidneys when administered ble involvement of oxidative stress in the pathogenesis of
orally at a dose of 12.5 mg/kg [26]. Our study suggests interstitial fibrosis in UUO [12]. Modification of proteins
that the differential effect on interstitial fibrosis of flu- and lipids by oxidative stress is believed to play a central
vastatin and pravastatin cannot be attributed to the bio- role in a variety of biological activities caused by in-
creased oxidative stress such as cell proliferation [35],availability of these drugs in the kidney in vivo.
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sion of adhesion molecules in rat renal cortex during experimentalapoptosis [36–38], and extracellular matrix expansion
hydronephrosis. Kidney Int 50:2002–2010, 1996
[39, 40]. It is tempting to establish the molecular link 9. Schreiner GF, Harris KPG, Purkerson ML, Klahr S: Immuno-
logical aspects of acute ureteral obstruction: Immune cell infiltratebetween oxidative stress and myofibroblast formation,
in the kidney. Kidney Int 34:487–493, 1988especially from the viewpoint of transcription factors.
10. Kaneto H, Morrissey J, Klahr S: Increased expression of TGF-
Our new findings regarding the regulatory mechanism beta 1 mRNA in the obstructed kidney of rats with unilateral
ureteral ligation. Kidney Int 44:313–321, 1993of a-SMA gene induction in myofibroblasts and involve-
11. Diamond JR, van Goor H, Ding G, Engelmyer E: Myofibroblastsment of oxidative stress described in the present study
in experimental hydronephrosis. Am J Pathol 146:121–129, 1995
may help to uncover the molecular link between oxida- 12. Kawada N, Moriyama T, Ando A, et al: Increased oxidative stress
in mouse kidneys with unilateral ureteral obstruction. Kidney Inttive stress and formation of myofibroblast and conse-
56:1004–1013, 1999quent fibrotic lesion in the kidney.
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